EpiCept is focused on developing novel therapies in the areas of cancer and pain.

Cancer

In the area of cancer, EpiCept has received approval from the European Commission for the use of Ceplene for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia in first remission. Two other product candidates are in clinical development for the treatment of solid tumors.

Pain

In the area of pain, the Company is advancing prescription pain products that use a topical delivery approach, as opposed to systemic or injectable modes, for both acute and chronic pain.

EpiCept invites you to learn more about these product candidates and their potential benefits to patients.

Development Pipeline